How does sapropterin work biochemically in phenylketonuria?
Sapropterin (a synthetic form of tetrahydrobiopterin, BH4) treats some cases of phenylketonuria (PKU) by acting as a cofactor for the liver enzyme phenylalanine hydroxylase (PAH). PAH normally converts phenylalanine into tyrosine. When BH4 is available, the PAH reaction can run more effectively, which lowers blood phenylalanine levels in responsive patients. That BH4-dependent pathway is the core biochemical mechanism behind sapropterin’s PKU effect.
What does BH4 change inside the phenylalanine-to-tyrosine pathway?
In PKU, phenylalanine accumulates because PAH activity is reduced (most commonly from PAH mutations). Providing BH4 can support PAH catalysis and stabilize the functional PAH enzyme state enough in some patients to increase phenylalanine breakdown. The biochemical “bottleneck” shifts from limited conversion capacity back toward the ability to hydroxylate phenylalanine, producing tyrosine instead of allowing phenylalanine to rise.
Why does sapropterin only help some people with PKU?
The BH4 cofactor strategy depends on whether enough PAH function can be restored or enhanced by adding BH4. Patients with PAH variants that still retain BH4 responsiveness may show a meaningful drop in phenylalanine. If PAH is severely impaired such that extra cofactor cannot restore activity, sapropterin has little or no effect.
What happens to phenylalanine and tyrosine levels during treatment?
When sapropterin improves PAH-mediated conversion, blood phenylalanine decreases because it is being processed into tyrosine. As phenylalanine falls, tyrosine production through this same pathway increases relative to untreated conditions—an expected biochemical consequence of moving flux from phenylalanine toward tyrosine.
What’s the relationship to PKU variants that affect BH4 itself?
Some rare hyperphenylalaninemias involve problems not only with PAH activity but also with BH4 availability or recycling. In those situations, supplementing BH4 can directly correct the cofactor deficit, changing the same BH4-dependent hydroxylation chemistry that underlies phenylalanine clearance.
How does sapropterin compare with dietary therapy from a mechanism standpoint?
Sapropterin does not replace the core need to limit phenylalanine intake in PKU; instead, it increases the body’s capacity to metabolize phenylalanine by boosting the BH4-dependent PAH step. Dietary restriction reduces phenylalanine load, while sapropterin aims to improve phenylalanine clearance kinetics through the residual PAH/BH4 pathway in BH4-responsive patients.